Laboratory of Molecular Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary, and.
János Szentágothai School of Neurosciences, Semmelweis University School of PhD Studies, 1085 Budapest, Hungary.
J Neurosci. 2019 Mar 27;39(13):2542-2561. doi: 10.1523/JNEUROSCI.1895-18.2019. Epub 2019 Jan 25.
Maternal immune activation (MIA) is a principal environmental risk factor contributing to autism spectrum disorder (ASD), which compromises fetal brain development at critical periods of pregnancy and might be causally linked to ASD symptoms. We report that endogenous activation of the purinergic ion channel P2X7 (P2rx7) is necessary and sufficient to transduce MIA to autistic phenotype in male offspring. MIA induced by poly(I:C) injections to P2rx7 WT mouse dams elicited an autism-like phenotype in their offspring, and these alterations were not observed in P2rx7-deficient mice, or following maternal treatment with a specific P2rx7 antagonist, JNJ47965567. Genetic deletion and pharmacological inhibition of maternal P2rx7s also counteracted the induction of IL-6 in the maternal plasma and fetal brain, and disrupted brain development, whereas postnatal P2rx7 inhibition alleviated behavioral and morphological alterations in the offspring. Administration of ATP to P2rx7 WT dams also evoked autistic phenotype, but not in KO dams, implying that P2rx7 activation by ATP is sufficient to induce autism-like features in offspring. Our results point to maternal and offspring P2rx7s as potential therapeutic targets for the early prevention and treatment of ASD. Autism spectrum disorder (ASD) is a neurodevelopmental psychiatric disorder caused by genetic and environmental factors. Recent studies highlighted the importance of perinatal risks, in particular, maternal immune activation (MIA), showing strong association with the later emergence of ASD in the affected children. MIA could be mimicked in animal models via injection of a nonpathogenic agent poly(I:C) during pregnancy. This is the first report showing the key role of a ligand gated ion channel, the purinergic P2X7 receptor in MIA-induced autism-like behavioral and biochemical features. We show that genetic or pharmacological inhibition of both maternal and offspring P2X7 receptors could reverse the compromised brain development and autistic phenotype pointing to new possibilities for prevention and treatment of ASD.
母体免疫激活 (MIA) 是导致自闭症谱系障碍 (ASD) 的主要环境风险因素,它会在妊娠的关键时期损害胎儿大脑发育,并可能与 ASD 症状有关。我们报告称,嘌呤能离子通道 P2X7 (P2rx7) 的内源性激活对于将 MIA 转化为雄性后代的自闭症表型是必要且充分的。聚肌苷酸 (poly(I:C)) 注射到 P2rx7 WT 鼠母鼠体内诱导的 MIA 会使其后代出现类似自闭症的表型,而在 P2rx7 缺陷小鼠或母体用特定的 P2rx7 拮抗剂 JNJ47965567 处理后则不会观察到这些改变。母体 P2rx7 的基因缺失和药理学抑制也会阻断母血浆和胎脑中 IL-6 的诱导,并破坏大脑发育,而产后 P2rx7 抑制则可减轻后代的行为和形态改变。向 P2rx7 WT 母鼠给予 ATP 也会引起自闭症表型,但在 KO 母鼠中则不会,这表明 ATP 激活 P2rx7 足以诱导后代出现自闭症样特征。我们的结果表明,母体和后代的 P2rx7 可能是 ASD 的早期预防和治疗的潜在治疗靶点。自闭症谱系障碍 (ASD) 是一种由遗传和环境因素引起的神经发育性精神障碍。最近的研究强调了围产期风险的重要性,特别是母体免疫激活 (MIA),这与受影响儿童 later 出现 ASD 有很强的关联。在怀孕期间,通过注射非致病性试剂 poly(I:C) 可以在动物模型中模拟 MIA。这是首次报道配体门控离子通道,嘌呤能 P2X7 受体在 MIA 诱导的自闭症样行为和生化特征中的关键作用。我们表明,母体和后代 P2X7 受体的遗传或药理学抑制都可以逆转受损的大脑发育和自闭症表型,为 ASD 的预防和治疗提供了新的可能性。